Cargando…

Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD‐11

AIM: To evaluate the impact of dulaglutide 3.0 and 4.5 mg versus 1.5 mg on body weight in patients with type 2 diabetes (T2D) based on exploratory analyses of the AWARD‐11 trial. MATERIALS AND METHODS: Patients were randomized to once‐weekly dulaglutide 1.5 (n = 612), 3.0 (n = 616) or 4.5 mg (n = 61...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bonora, Enzo, Frias, Juan P., Tinahones, Francisco J., Van, Joanna, Malik, Raleigh E., Yu, Zhuoxin, Mody, Reema, Bethel, Angelyn, Kwan, Anita Y. M., Cox, David A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518850/ https://www.ncbi.nlm.nih.gov/pubmed/34189841 http://dx.doi.org/10.1111/dom.14465

Ejemplares similares

Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)
por: Frias, Juan P., et al.
Publicado: (2021)

Efficacy of Dulaglutide Expanded Doses by Baseline A1C Categories: Post Hoc Analysis of AWARD-11
por: Frias, Juan Pablo, et al.
Publicado: (2021)

Gastrointestinal Tolerability of Once-Weekly Dulaglutide 3.0 mg and 4.5 mg: A Post Hoc Analysis of the Incidence and Prevalence of Nausea, Vomiting, and Diarrhea in AWARD-11
por: Van, Joanna, et al.
Publicado: (2021)

Efficacy and safety of dulaglutide 3.0 and 4.5 mg in patients aged younger than 65 and 65 years or older: Post hoc analysis of the AWARD‐11 trial
por: Frias, Juan P., et al.
Publicado: (2021)

Glycaemic efficacy of an expanded dose range of dulaglutide according to baseline glycated haemoglobin (HbA1c) subgroup: Post hoc analysis of AWARD‐11
por: Frias, Juan P., et al.
Publicado: (2021)

Effect of expanded dulaglutide weekly doses (3.0 mg and 4.5 mg) on cardiovascular disease risk factors in participants with type 2 diabetes at increased cardiovascular disease risk: a post hoc analysis of the AWARD‐11 study
por: Cox, David A., et al.
Publicado: (2022)

OR26-08 Efficacy and Safety of Higher Dulaglutide Doses (3.0 MG and 4.5 MG) When Added to Metformin in Patients With Type 2 Diabetes: A Phase 3, Randomized, Double-Blind, Parallel ARM Study (Award-11)
por: Frias, Juan Pablo, et al.
Publicado: (2020)

An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg
por: Pratley, Richard E., et al.
Publicado: (2021)

Real-World Effectiveness of Dulaglutide in Patients with Type 2 Diabetes Mellitus: A Literature Review
por: Robinson, Susan, et al.
Publicado: (2020)

An Indirect Treatment Comparison of Semaglutide 2.0 mg vs Dulaglutide 3.0 mg and 4.5 mg Using Multilevel Network Meta-regression
por: Lingvay, Ildiko, et al.
Publicado: (2021)

A model‐based simulation of glycaemic control and body weight when switching from semaglutide to 3.0‐ and 4.5‐mg doses of once‐weekly dulaglutide
por: Tham, Lai San, et al.
Publicado: (2021)

The long-term cost-effectiveness of once-weekly semaglutide 1 mg vs. dulaglutide 3 mg and 4.5 mg in the UK
por: Viljoen, Adie, et al.
Publicado: (2022)

Dulaglutide and Insulin: How Can the AWARD Studies Help Guide Clinical Practice?
por: MacIsaac, Richard J.
Publicado: (2020)

Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND
por: Konig, Manige, et al.
Publicado: (2021)

OR30-06 Assessment of Dulaglutide Safety in Older Patient Populations in Rewind
por: Konig, Manige, et al.
Publicado: (2020)

Adherence and persistence among patients with type 2 diabetes initiating dulaglutide compared with semaglutide and exenatide BCise: 6‐month follow‐up from US real‐world data
por: Mody, Reema, et al.
Publicado: (2020)

Clinical and economic outcomes among injection-naïve patients with type 2 diabetes initiating dulaglutide compared with basal insulin in a US real-world setting: the DISPEL Study
por: Mody, Reema, et al.
Publicado: (2019)

Effect of once weekly dulaglutide by baseline beta‐cell function in people with type 2 diabetes in the AWARD programme
por: Mathieu, Chantal, et al.
Publicado: (2018)

NAPCON AWARD-30
Publicado: (2015)

Achieving the composite endpoint of glycated haemoglobin <7.0%, no weight gain and no hypoglycaemia in the once‐weekly dulaglutide AWARD programme
por: Dungan, K. M., et al.
Publicado: (2016)

Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon‐like peptide‐1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once‐weekly exenatide and liraglutide
por: Alatorre, Carlos, et al.
Publicado: (2017)

Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12‐month follow‐up in a real‐world setting in the United States
por: Mody, Reema, et al.
Publicado: (2019)

Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)
por: Nauck, Michael, et al.
Publicado: (2014)

A 24‐week study to evaluate the efficacy and safety of once‐weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD‐8)
por: Dungan, K. M., et al.
Publicado: (2016)

Necrotizing Pancreatitis Secondary to Dulaglutide Use
por: Bhat, Salman Zahoor, et al.
Publicado: (2021)

Efficacy and Safety of Once-Weekly Dulaglutide in Elderly Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN Studies
por: Kuang, Jian, et al.
Publicado: (2020)

The Cost-effectiveness of Dulaglutide 1.5mg versus Exenatide QW for the Treatment of Patients with Type 2 Diabetes Mellitus in France
por: Basson, Mickael, et al.
Publicado: (2017)

Efficacy and Safety of Once-Weekly Dulaglutide in Type 2 Diabetes Patients Using Insulin: Exploratory Subgroup Analysis by Insulin Regimen
por: Onishi, Yukiko, et al.
Publicado: (2020)

Mode of administration of dulaglutide: implications for treatment adherence
por: Amblee, Ambika
Publicado: (2016)

Dulaglutide Alleviates LPS-Induced Injury in Cardiomyocytes
por: Wang, Rijun, et al.
Publicado: (2021)

Exacerbation of atrial fibrillation related to dulaglutide use
por: Lee, Jayden, et al.
Publicado: (2021)

A Case of Dulaglutide-Induced Vaginal Bleed
por: Vaccaro, Christopher J, et al.
Publicado: (2023)

Efficacy and Safety of Dulaglutide Versus Insulin Glargine in Chinese T2DM Patients: A Subgroup Analysis of a Randomized Trial (AWARD-CHN2)
por: Li, Yan, et al.
Publicado: (2019)

Efficacy of Dulaglutide in Chinese Patients with Type 2 Diabetes and Different Glycemic Patterns: a Post-hoc Analysis of the Phase 3 AWARD-CHN2 Trial
por: Li, Qifu, et al.
Publicado: (2021)

Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison
por: Vadher, Karan, et al.
Publicado: (2022)

Dulaglutide 1.5 mg as an add‐on option for patients uncontrolled on insulin: Subgroup analysis by age, duration of diabetes and baseline glycated haemoglobin concentration
por: Pantalone, Kevin M., et al.
Publicado: (2018)

Advances in the treatment of type 2 diabetes: impact of dulaglutide
por: Thompson, Angela M, et al.
Publicado: (2016)

An Uncommon Case of Dulaglutide-Related Morbilliform Drug Eruption
por: Kyriakos, Georgios, et al.
Publicado: (2022)

Correction to Dulaglutide Alleviates LPS-Induced Injury in Cardiomyocytes
por: Wang, Rijun, et al.
Publicado: (2022)

Efficacy and Safety of Dulaglutide in Type 2 Diabetes Patients in Endocrinology Clinics of Islamabad, Pakistan
por: Kamin, Matiullah, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_h2fh59b26um9njtvjf53mjcoa6